Following the latest Drug Target Review webinar, supported by Analytik Jena, we put the audience’s questions to the speakers to understand how hardware, software and labware challenges can be successfully overcome.
List view / Grid view
Dr Ronald G Crystal, Professor and Chairman of the Department of Genetic Medicine, Weill Cornell Medical College, spoke to Drug Target Review’s Victoria Rees about his research into Alzheimer’s disease and why gene therapies represent a promising area of research for neurodegenerative conditions.
Researchers at the University of East Finland have been using skin cells to investigate pathological hallmarks in frontotemporal dementia patients.
Researchers have identified a process that amplifies changes in gene expression, which could be harnessed to accelerate stem cell differentiation.
In this exclusive report, find an in-depth analysis of AI and informatics within imaging, synthetic biology, drug screening and drug design. Featured interviews with experts from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
In this interview, read about the compilation of a new high-resolution cell atlas of the mouse brain using spatial genomics and transcriptomics.
In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
How engineered RNA binding proteins delivered in vivo by gene therapy could treat myotonic dystrophy
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
Transcriptional reprogramming rescues vascular fate of misidentified pluripotent cell‑derived epithelial cells
A team of scientists has found that a type of cell derived from human stem cells and widely used for brain research and drug development may have been leading researchers astray for years. Here, Dr Raphaël Lis from Weill Cornell Medicine explains how forcing the activity of three known endothelial cell transcription…
To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outlines his research into liver organoids derived from stem cells that can be used to test new…
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
Inherited blindness is the leading cause of vision loss in the working populations. Recently, the first gene therapy for the treatment of retinal dystrophy caused by mutations in the RPE65 gene became available. This gene therapy is based on adeno-associated virus (AAV) vectors injected under the retina. Subretinal injection is…